dr. reddy's laboratories news

Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow

RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.

Mint · 1d

Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY

The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.

Hosted on MSN · 18h

Dr Reddy's Q2 performance sees revenue boost, but challenges persist

Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong 16.5 percent year-on-year rise, slightly exceeding the estimate of Rs 7,854 crore.

Reuters on MSN · 1d

India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge

By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,

Press Trust of India on MSN · 1d

Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc

Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,

MarketWatch12h

Dr. Reddy's Laboratories outperforms competitors on strong trading day

Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...

Dr. Reddy’s Labs Releases Unaudited Financial Results

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has released its unaudited financial results for the ...

ndtvprofit12h

Dr Reddy's Aims To Consistently Deliver Double-Digit Sales Growth, Ebitda Margin Of 25%

Dr Reddy's expects overall sales to grow in double digits, with branded business in India and emerging markets growing in ...

Dr. Reddy's Laboratories rises Tuesday, still underperforms market

Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...

Dr Reddy’s Laboratories (RDY) Gets a Buy from Barclays

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...

cnbctv1819h

Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2

Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.

Neutral Dr Reddys Laboratories; target of Rs 1390: Motilal Oswal

Motilal Oswal recommended Neutral rating on Dr Reddys Laboratories with a target price of Rs 1390 in its research report ...

ndtvprofit18h

Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom

Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.

Business Insider18h

Dr. Reddy’s Reports Strong Q2FY25 Results and Strategic Expansions

Dr. Reddy’s Laboratories Ltd ( (RDY)) has released its Q2 earnings. Here is a breakdown of the information Dr. Reddy’s Laboratories Ltd presented to its investors. Dr. Reddy’s ...

Reduce Dr. Reddy's Laboratories; target of Rs 1335 Prabhudas Lilladher

Dr. Reddy’s (DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics